Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Sanja Dacic, MD, PhD; Isabel Preeshagul, DO, MBS; and Soo-Ryum (Stewart) Yang, MD, discuss cases of patients with non–small cell lung cancer harboring actionable alterations.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Interpret tissue and liquid biopsy–based molecular testing results to support appropriate treatment selection for actionable mutations
• Evaluate emerging and established clinical trial data on targeted therapies in NSCLC
• Identify strategies to overcome barriers to biomarker testing and enhance collaboration between pathology and oncology teams for optimal patient care

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from Lilly, Nuvation Bio, and Revolution Medicines.

Chair:

Sanja Dacic, MD, PhD

Vice-Chair and Director of Anatomic Pathology
Department of Pathology
Yale School of Medicine
New Haven, CT

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca

Faculty:

Isabel Preeshagul, DO, MBS

Thoracic Medical Oncologist
Memorial Sloan Kettering Cancer Center,
Bergen
Montvale, NJ

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, COR2ED GmbH, Dava Oncology, IDEOlogy Health, Johnson & Johnson, Medscape, Pfizer, Plexus Communications, Regeneron Pharmaceuticals, Takeda Pharmaceuticals

Soo-Ryum (Stewart) Yang, MD

Assistant Attending Pathologist
Molecular Diagnostics and Thoracic Pathology
Co-Director, Clinical Biomarker Development
Early Drug Development Service (Solid Tumor)
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AbbVie, Amgen, AstraZeneca, Eli Lilly, Merus, Revolution Medicines, Roche, Sanofi

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on additional actionable biomarkers to tailor treatment for NSCLC, go to https://www.gotoper.com/pathology26nsclc-activity.

Release Date

May 6, 2026

Expiration Date

May 6, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.